Skip to content
Back to Blog
Bio
2026-10-267 min read3

Drug Price Premium for Domestic APIs, Yet Zero Applications — The Limits of the 'In-House Manufacturing' Requirement Flagged in Korea's 2026 National Audit and a 31.4% API Self-Sufficiency Rate: What SME Pharma and API Makers Should Review Now in Sourcing, DMF and Product Strategy

Korea's price premium for drugs made with domestic APIs drew zero applications, as the 2026 National Audit revealed, because only in-house API manufacturing qualifies. This post looks at the 31.4% self-sufficiency rate and what SME pharma and API makers should review now in sourcing, DMFs and product strategy.

KITIM Consulting Team

Zero Applications at the National Audit — What the Scheme Is and Why No One Applied

When Korea overhauled its drug pricing system, it added a price premium for finished drugs made with active pharmaceutical ingredients (APIs) produced domestically. The goal was to reduce dependence on imported APIs and stabilize the supply chain.

At the 2026 National Assembly audit of the Health Insurance Review and Assessment Service (HIRA), however, it emerged that not a single company had applied for or received the premium. Lawmakers said the scheme had produced "zero incentive" for API self-sufficiency.

The problem is the eligibility rule. The premium currently applies only when the marketing authorization holder of the finished drug synthesizes the API itself, including the chemical conversion steps, at its own manufacturing site. Domestic APIs sourced from an affiliate or a specialist API maker do not count. Critics note that this ignores how Korea's industry actually works: API and finished-dose manufacturing have long been separate businesses.

The Dependence in Numbers

  • Korea's API self-sufficiency rate was 31.4% in 2024, up sharply from 11.9% in 2022
  • That figure includes biologic APIs such as biosimilars. For chemical generics, the effective rate is only in the low 20s
  • Self-sufficiency for penicillin-class APIs has been 0% for five straight years
  • China (36.3%), India (14.2%) and Japan (9.0%) together account for roughly 60% of API imports
  • When a single API runs short, production of the finished drug stops, and that quickly becomes a shortage or supply discontinuation. Other governments treat this as a policy priority: the US is pursuing API stockpiling and onshoring, the EU is advancing a Critical Medicines Act, and Japan supports domestic production of antibiotic APIs.

    Where Reform Talk Is Heading, and What Remains Uncertain

    Options raised at the audit and by industry include:

  • Counting APIs made by affiliates
  • Counting APIs sourced from domestic specialist API manufacturers
  • Targeting support at strategic products instead of applying the premium across the board
  • That said, no revised rule has been finalized. Whether the requirement will change, and when, depends on follow-up announcements from the Ministry of Health and Welfare. Even if the rule is relaxed, companies will most likely still need documented proof that the API is domestic to qualify.

    What SME Finished-Dose Manufacturers Should Do Now

    1. Map your API supply chain

  • For each product, record the API source (country and site), DMF registration status and any alternative suppliers
  • Flag single-source products as your highest-risk items
  • 2. Estimate switching cost and time

  • Changing an API manufacturer means a variation filing, stability studies and, where needed, bioequivalence re-evaluation
  • If you estimate the time and cost per product now, you can act as soon as the rule changes
  • 3. Set product selection criteria

  • With continued downward pressure on prices, drop low-margin products and shortlist premium candidates based on revenue, supply criticality and availability of a domestic API
  • An Opportunity for API Manufacturers?

    A relaxed rule could raise finished-dose makers' demand for domestic APIs. Price alone won't win contracts, though. Customers will take on the burden of a variation filing only if the supplier has solid GMP compliance and DMF capability.

  • Pairing production with government R&D and facility programs for essential-medicine APIs and process improvement can make your costs more competitive
  • The strongest sales pitch is usually not "we're cheaper" but "dual sourcing lowers your shortage risk"
  • Action Checklist and How KITIM Can Help

  • Diagnose your API supply chain: sources, DMFs and alternative suppliers for each product
  • Select candidate products to switch: based on revenue, supply risk and domestic API availability
  • Plan the regulatory changes: timelines and costs for variations, stability and BE work
  • Monitor policy changes: track MOHW and HIRA announcements and act on them quickly
  • KITIM helps pharma and bio companies plan GMP readiness, regulatory variation strategy and access to government programs for API self-sufficiency. If you are reviewing your API sourcing or considering a switch to domestic APIs, contact the KITIM consulting team. We will work with you on an action plan tailored to your product portfolio.

    Active Pharmaceutical IngredientsDomestic API Price PremiumAPI Self-SufficiencyDrug Pricing ReformNational AuditDMFSME Pharmaceutical CompaniesPharmaceutical Supply Chain

    Related Posts

    Bio

    Korea's Incremental Modified Drug Criteria Revised After Four Years — MFDS Guideline Updated Oct 30, 2026 (Container Improvement Removed, Broader Non-PK Evidence, No Recognition for Simple Salt Changes): Development Planning and Evidence Design for Pharma SMEs Moving Beyond Generics

    MFDS revised its incremental modified drug recognition guideline on October 30, 2026, for the first time in four years: container improvement is gone, simple salt changes are explicitly excluded, and evidence beyond PK data can now count. This guide shows pharma SMEs how to reassess ongoing projects and design their evidence.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Smart Factory

    The Government Pays for the Build, You Pay to Keep It Running — Software Subscriptions and AI Model Retraining Costs Outside the 2027 Manufacturing-AI Smart Factory Support, and How SMEs Should Budget 3–5 Years of Operation Before Applying

    The 2027 Manufacturing-AI Smart Factory program reportedly offers up to KRW 200 million (70% support outside the capital region), but software subscriptions and AI retraining costs fall outside its scope. This guide shows how to build a 3–5 year TCO table, negotiate vendor terms, and present an operating plan in your proposal before you apply.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.